Published in Lancet on June 25, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Tumor adaptation and resistance to RAF inhibitors. Nat Med (2013) 3.11
Vemurafenib: the first drug approved for BRAF-mutant cancer. Nat Rev Drug Discov (2012) 3.09
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study. JAMA Intern Med (2014) 2.50
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst (2015) 2.31
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol (2015) 2.00
Strategies for modern biomarker and drug development in oncology. J Hematol Oncol (2014) 1.89
Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest (2014) 1.81
High frequency of BRAF V600E mutations in ameloblastoma. J Pathol (2014) 1.79
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77
Key role of CRF in the skin stress response system. Endocr Rev (2013) 1.77
The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. P T (2013) 1.68
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med (2013) 1.67
Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell (2013) 1.67
Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol (2014) 1.64
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther (2012) 1.60
Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma. Mol Cancer (2014) 1.59
PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov (2014) 1.58
Melanoma resistance: a bright future for academicians and a challenge for patient advocates. Mayo Clin Proc (2014) 1.57
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol (2014) 1.55
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol (2014) 1.53
Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Hum Pathol (2013) 1.50
Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol (2014) 1.47
Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. JAMA Oncol (2016) 1.45
A costly revolution for a subgroup of patients with metastatic melanoma. Br J Dermatol (2013) 1.44
Selective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs. PLoS One (2015) 1.43
Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma. PLoS One (2014) 1.42
Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist (2013) 1.41
Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. J Natl Cancer Inst (2016) 1.40
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science (2014) 1.37
The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways. Arch Biochem Biophys (2014) 1.36
Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One (2013) 1.34
The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One (2012) 1.34
Medical management of malignant melanoma. Aust Prescr (2015) 1.33
Resistance to RAF inhibitors revisited. J Invest Dermatol (2013) 1.33
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget (2014) 1.33
Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol (2015) 1.33
Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma. Mol Diagn Ther (2017) 1.32
Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clin Cancer Res (2015) 1.31
Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Res (2013) 1.31
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int (2015) 1.25
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther (2012) 1.25
The MAPK pathway across different malignancies: a new perspective. Cancer (2014) 1.22
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res (2014) 1.21
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. Cancer Res (2014) 1.20
A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. Cancer Gene Ther (2015) 1.19
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther (2014) 1.18
Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol Res (2014) 1.17
Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 1.16
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A (2014) 1.15
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer (2013) 1.14
B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol (2013) 1.14
Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget (2015) 1.12
Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. Br J Cancer (2013) 1.10
The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res (2013) 1.10
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist (2013) 1.08
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res (2014) 1.08
BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer (2013) 1.08
BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? Curr Treat Options Oncol (2017) 1.06
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Lancet Oncol (2016) 1.06
Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc (2014) 1.06
Mutation-specific antibody detects mutant BRAFV600E protein expression in human colon carcinomas. Cancer (2013) 1.06
Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica (2013) 1.06
MEK inhibition in non-small cell lung cancer. Lung Cancer (2014) 1.05
AACR Cancer Progress Report 2014. Clin Cancer Res (2014) 1.05
Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol (2015) 1.04
Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov (2014) 1.03
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood (2014) 1.03
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget (2015) 1.02
Atg7 Overcomes Senescence and Promotes Growth of BrafV600E-Driven Melanoma. Cancer Discov (2015) 1.02
Targeting the RAS oncogene. Expert Opin Ther Targets (2013) 1.02
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. Elife (2013) 1.02
Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Front Oncol (2015) 1.02
Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep (2013) 1.01
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. ACS Med Chem Lett (2013) 1.00
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget (2015) 1.00
Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. Front Oncol (2014) 1.00
Phenotype switching in melanoma: implications for progression and therapy. Front Oncol (2015) 1.00
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer (2015) 0.99
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 0.99
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther (2015) 0.99
Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation. Clin Cancer Res (2014) 0.98
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene (2015) 0.98
MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer (2014) 0.98
The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas. Front Oncol (2013) 0.98
Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutations. Clin Cancer Res (2014) 0.98
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Randomized controlled trial testing the impact of high-protection sunscreens on sun-exposure behavior. Arch Dermatol (2005) 9.42
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol (2003) 5.84
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 4.58
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol (2004) 4.37
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol (2011) 4.19
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol (2004) 4.06
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst (2007) 3.60
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
KIT as a therapeutic target in metastatic melanoma. JAMA (2011) 3.49
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Histamine down-regulates IL-27 production in antigen-presenting cells. J Leukoc Biol (2012) 3.12
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res (2009) 3.10
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer (2010) 2.73
IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol (2009) 2.64
Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol (2011) 2.62
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med (2010) 2.47
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA (2005) 2.37
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res (2010) 2.31
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood (2009) 2.31
Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med (2003) 2.30
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer (2009) 2.26
Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. J Clin Oncol (2013) 2.22
Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med (2012) 2.19
Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist (2007) 2.17
Oxalic acid excretion after intravenous ascorbic acid administration. Metabolism (2009) 2.14
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer (2012) 2.05
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood (2008) 2.04
Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res (2008) 2.04
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One (2013) 2.01
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol (2002) 1.98
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
A case of squamous cell carcinoma of the scalp after several synthetic hair grafts. Aesthetic Plast Surg (2012) 1.92
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res (2008) 1.82
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol (2003) 1.77
Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer. Acta Oncol (2006) 1.77
Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer (2006) 1.75
Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J Invest Dermatol (2009) 1.75
Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. J Invest Dermatol (2008) 1.73
Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol (2011) 1.73
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol (2008) 1.67
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 1.67
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma. Cancer (2010) 1.66
Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients. Ann Surg Oncol (2008) 1.65
MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer (2010) 1.62
Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol (2008) 1.58
Prognostic significance of isolated HMB45 or Melan A positive cells in Melanoma sentinel lymph nodes. Am J Surg Pathol (2007) 1.58
Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest (2007) 1.56
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res (2013) 1.55
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res (2014) 1.55